4 Things You Need to Know if You Buy Moderna Stock Today

It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine playing a landmark role in tackling the global pandemic in late 2020. Despite its generating record sales and profits through 2022, early projections of sustained demand for coronavirus vaccinations failed to materialize, leading to a sharp drop in the business. Shareholders haven't been immune to a deep reset in the company's expectations, with the stock losing 92% of its value from its all-time high.Yet, not all is lost for Moderna, which maintains some key fundamental strengths, including an extensive pipeline of new product candidates and a strong balance sheet supporting a more positive, long-term outlook. Here are five things you should know if you're considering buying Moderna stock now.Moderna is recognized as a pioneer in messenger RNA (mRNA) technology, seen as a potential game changer in medicine. This technology uses the body's cellular machinery to fight diseases by directing cells to produce proteins that trigger a specific immune response or address a particular health issue. As proven by the success of the Spikevax COVID-19 vaccine, Moderna aims to build on this achievement by expanding into applications for influenza, cancer, and rare diseases.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool